当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2013年第3期 > 正文
编号:12360428
磺达肝癸钠对非ST段抬高急性冠脉综合征的疗效与安全性的研究(2)
http://www.100md.com 2013年1月25日 杨超 李彦 杨永忠
第1页

    参见附件。

     综上所述,磺达肝癸钠有和普通肝素和低分子肝素同样的疗效,甚至优于这些药物,但出血风险大大下降,因此在临床上存在广阔的应用前景。

    [参考文献]

    [1] Piccini JP,Hranitzky P. Diagnostic monitoring strategies in heart failure management [J]. Am Heart J,2007,153(4 Suppl):12217.

    [2] 柯元南.急性冠脉综合征诊断和治疗进展[J].中华老年心脑血管病杂志,2006,8(1):24.

    [3] Varin R,Mirshahi S,Mirshahi P,et al. Clot structure modification by fondaparinux and consequence on fibrinolysis:a new mechanism of antithrombotic activity [J]. Thromb Haemost,2007,97:27-31.

    [4] Gerotziafas GT,Depasse F,Chakroun T,et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood [J]. Thromb Haemost,2004,91:531-537.

    [5] Huvers F,Slappendel R,Benraad B,et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid [J]. Neth J Med,2005,63:184-186.

    [6] Paolucci F,Clavies MC,Donat F,et al. Fondaparinux sodium mechanism of action:identification of specific binding to purified and human plasma-derived proteins [J]. Clin Pharmacokinet,2002,41(suppl):11-18.

    [7] Smogorzewska A,Brandt JT,Chandler WL,et al. Effect of fondaparinux on coagulation assays:results of College of American Pathologists proficiency testing [J]. Arch Pathol Lab Med,2006,130:1605-1611.

    [8] Yusuf S,Mehta SR,Chrolavicius S,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes [J]. N Engl J Med,2006, 354(14):1464-1476.

    (收稿日期:2012-08-21 本文编辑:张瑜杰)

您现在查看是摘要介绍页,详见PDF附件(3394kb)